Information Provided By: 
Fly News Breaks for February 25, 2019
EXEL
Feb 25, 2019 | 17:09 EDT
Cowen analyst Yaron Werber assumed coverage of Exelixis with an Outperform rating and $29 price target. Werber noted that, "after strong growth, Cabometyx is facing intense competition that may pressure sales," but the analyst anticipates positive Phase 3 data from CHECKMATE-9ER in the second half of 2019 re-accelerating growth. Werber also believes that "recent strong bids for oncology companies may put Exelixis at play for takeout."
News For EXEL From the Last 2 Days
There are no results for your query EXEL
